<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36070178</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Nuclear Pore Dysfunction in Neurodegeneration.</ArticleTitle><Pagination><StartPage>1050</StartPage><EndPage>1060</EndPage><MedlinePgn>1050-1060</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-022-01293-w</ELocationID><Abstract><AbstractText>The nuclear pore complex (NPC) is a large multimeric structure that is interspersed throughout the membrane of the nucleus and consists of at least 33 protein components. Individual components cooperate within the nuclear pore to facilitate selective passage of materials between the nucleus and cytoplasm while simultaneously performing pore-independent roles throughout the cell. NPC dysfunction is a hallmark of neurodegenerative disorders including Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). NPC components can become mislocalized or altered in expression in neurodegeneration. These alterations in NPC structure are often detrimental to the neuronal function and ultimately lead to neuronal loss. This review highlights the importance of nucleocytoplasmic transport and NPC integrity and how dysfunction of such may contribute to neurodegeneration.</AbstractText><CopyrightInformation>&#xa9; 2022. The American Society for Experimental Neurotherapeutics, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spead</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaepfel</LastName><ForeName>Benjamin L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-2001-8470</Identifier><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. jrothst1@jh.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. jrothst1@jh.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022022" MajorTopicYN="Y">Nuclear Pore</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Nuclear pore complex</Keyword><Keyword MajorTopicYN="N">Nucleocytoplasmic transport</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>7</Day><Hour>13</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36070178</ArticleId><ArticleId IdType="pmc">PMC9587172</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01293-w</ArticleId><ArticleId IdType="pii">10.1007/s13311-022-01293-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singer RH, Green MR. Compartmentalization of eukaryotic gene expression: causes and effects. Cell. 1997;91:291&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363936</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabrini R, Bocedi A, Pallottini V, Canuti L, De Canio M, Urbani A, Marzano V, Cornetta T, Stano P, Giovanetti A, Stella L, Canini A, Federici G, Ricci G. Nuclear shield: a multi-enzyme task-force for nucleus protection. PLoS ONE. 2010;5:e14125&#x2013;e14125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000810</ArticleId><ArticleId IdType="pubmed">21170318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DH, Hoelz A. The structure of the nuclear pore complex (an update) Annu Rev Biochem. 2019;88:725&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588426</ArticleId><ArticleId IdType="pubmed">30883195</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas JN, Toyama BH, Xu T, Yates JR, 3rd, Hetzer MW. Extremely long-lived nuclear pore proteins in the rat brain. Science. 2012;335:942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296478</ArticleId><ArticleId IdType="pubmed">22300851</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigg EA. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature. 1997;386:779&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126736</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;rlich D, Mattaj IW. Nucleocytoplasmic transport. Science. 1996;271:1513&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pubmed">8599106</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatel G, Fahrenkrog B. Dynamics and diverse functions of nuclear pore complex proteins. Nucleus. 2012;3:162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383572</ArticleId><ArticleId IdType="pubmed">22555605</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AU, Qu R, Ouyang J, Dai J. Role of nucleoporins and transport receptors in cell differentiation. Front Physiol. 2020;11:239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145948</ArticleId><ArticleId IdType="pubmed">32308628</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmi V, Sakuma S, D'Angelo MA. Nuclear pore complexes in development and tissue homeostasis. Development. 2020;147:dev183442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758637</ArticleId><ArticleId IdType="pubmed">33323374</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitanio JS, Montpetit B, Wozniak RW. Human Nup98 regulates the localization and activity of DExH/D-box helicase DHX9. eLife. 2017;6:e18825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338925</ArticleId><ArticleId IdType="pubmed">28221134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, Meyerson M, Sabatini DM. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013;340:1100&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728654</ArticleId><ArticleId IdType="pubmed">23723238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson RL, Chantranupong L, Wyant GA, Gu X, Orozco JM, Shen K, Condon KJ, Petri S, Kedir J, Scaria SM, Abu-Remaileh M, Frankel WN, Sabatini DM. KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. Nature. 2017;543:438&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360989</ArticleId><ArticleId IdType="pubmed">28199306</ArticleId></ArticleIdList></Reference><Reference><Citation>Neilson DE, Adams MD, Orr CM, Schelling DK, Eiben RM, Kerr DS, Anderson J, Bassuk AG, Bye AM, Childs AM, Clarke A, Crow YJ, Di Rocco M, Dohna-Schwake C, Dueckers G, Fasano AE, Gika AD, Gionnis D, Gorman MP, Grattan-Smith PJ, Hackenberg A, Kuster A, Lentschig MG, Lopez-Laso E, Marco EJ, Mastroyianni S, Perrier J, Schmitt-Mechelke T, Servidei S, Skardoutsou A, Uldall P, van der Knaap MS, Goglin KC, Tefft DL, Aubin C, de Jager P, Hafler D, Warman ML. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet. 2009;84:44&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668029</ArticleId><ArticleId IdType="pubmed">19118815</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JM, Ahsan N, Ho E, Santoro JD. Genetic acute necrotizing encephalopathy associated with RANBP2: clinical and therapeutic implications in pediatrics. Mult Scler Relat Disord. 2020;43:102194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228726</ArticleId><ArticleId IdType="pubmed">32426208</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamada M, Haeger A, Jeganathan KB, van Ree JH, Malureanu L, W&#xe4;lde S, Joseph J, Kehlenbach RH, van Deursen JM. Ran-dependent docking of importin-beta to RanBP2/Nup358 filaments is essential for protein import and cell viability. J Cell Biol. 2011;194:597&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160583</ArticleId><ArticleId IdType="pubmed">21859863</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetter IR, Nowak C, Nishimoto T, Kuhlmann J, Wittinghofer A. Structure of a Ran-binding domain complexed with Ran bound to a GTP analogue: implications for nuclear transport. Nature. 1999;398:39&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cautain B, Hill R, de Pedro N, Link W. Components and regulation of nuclear transport processes. Febs j. 2015;282:445&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163960</ArticleId><ArticleId IdType="pubmed">25429850</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama N, Hayashi N, Seki T, Pant&#xe9; N, Ohba T, Nishii K, Kuma K, Hayashida T, Miyata T, Aebi U, et al. A giant nucleopore protein that binds Ran/TC4. Nature. 1995;376:184&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">7603572</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh BB, Patel HH, Roepman R, Schick D, Ferreira PA. The zinc finger cluster domain of RanBP2 is a specific docking site for the nuclear export factor, exportin-1. J Biol Chem. 1999;274:37370&#x2013;37378.</Citation><ArticleIdList><ArticleId IdType="pubmed">10601307</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa Braslavsky CI, Nowak C, G&#xf6;rlich D, Wittinghofer A, Kuhlmann J. Different structural and kinetic requirements for the interaction of Ran with the Ran-binding domains from RanBP2 and importin-beta. Biochemistry. 2000;39:11629&#x2013;11639.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho KI, Yoon D, Qiu S, Danziger Z, Grill WM, Wetsel WC, Ferreira PA. Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes. Dis Model Mech. 2017;10:559&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451164</ArticleId><ArticleId IdType="pubmed">28100513</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil H, Saha A, Senda E, Cho KI, Haque M, Yu M, Qiu S, Yoon D, Hao Y, Peachey NS, Ferreira PA. Selective impairment of a subset of Ran-GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation. J Biol Chem. 2014;289:29767&#x2013;29789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4207991</ArticleId><ArticleId IdType="pubmed">25187515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb HM, Folkmann AW, Belzil VV, Jao LE, Leblond CS, Girard SL, Daoud H, Noreau A, Rochefort D, Hince P, Szuto A, Levert A, Vidal S, Andr&#xe9;-Guimont C, Camu W, Bouchard JP, Dupr&#xe9; N, Rouleau GA, Wente SR, Dion PA. Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum Mol Genet. 2015;24:1363&#x2013;1373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321443</ArticleId><ArticleId IdType="pubmed">25343993</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy R, Wente SR. An RNA-export mediator with an essential nuclear export signal. Nature. 1996;383:357&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">8848052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendirgi F, Barry DM, Griffis ER, Powers MA, Wente SR. An essential role for hGle1 nucleocytoplasmic shuttling in mRNA export. J Cell Biol. 2003;160:1029&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172758</ArticleId><ArticleId IdType="pubmed">12668658</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendirgi F, Rexer DJ, Alc&#xe1;zar-Rom&#xe1;n AR, Onishko HM, Wente SR. Interaction between the shuttling mRNA export factor Gle1 and the nucleoporin hCG1: a conserved mechanism in the export of Hsp70 mRNA. Mol Biol Cell. 2005;16:4304&#x2013;4315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1196339</ArticleId><ArticleId IdType="pubmed">16000379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayala HJ, Kendirgi F, Barry DM, Majerus PW, Wente SR. The mRNA export factor human Gle1 interacts with the nuclear pore complex protein Nup155. Mol Cell Proteomics. 2004;3:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jao LE, Appel B, Wente SR. A zebrafish model of lethal congenital contracture syndrome 1 reveals Gle1 function in spinal neural precursor survival and motor axon arborization. Development. 2012;139:1316&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3294435</ArticleId><ArticleId IdType="pubmed">22357925</ArticleId></ArticleIdList></Reference><Reference><Citation>Herva R, Conradi NG, Kalimo H, Leisti J, Sourander P. A syndrome of multiple congenital contractures: neuropathological analysis on five fetal cases. Am J Med Genet. 1988;29:67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">3344776</ArticleId></ArticleIdList></Reference><Reference><Citation>Nousiainen HO, Kestil&#xe4; M, Pakkasj&#xe4;rvi N, Honkala H, Kuure S, Tallila J, Vuopala K, Ignatius J, Herva R, Peltonen L. Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat Genet. 2008;40:155&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684619</ArticleId><ArticleId IdType="pubmed">18204449</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkmann AW, Collier SE, Zhan X, Aditi. Ohi MD, Wente SR. Gle1 functions during mRNA export in an oligomeric complex that is altered in human disease. Cell. 2013;155:582&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855398</ArticleId><ArticleId IdType="pubmed">24243016</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuopala K, Ignatius J, Herva R. Lethal arthrogryposis with anterior horn cell disease. Hum Pathol. 1995;26:12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">7821908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kind B, Koehler K, Lorenz M, Huebner A. The nuclear pore complex protein ALADIN is anchored via NDC1 but not via POM121 and GP210 in the nuclear envelope. Biochem Biophys Res Commun. 2009;390:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782045</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazumi Y, Kamiya A, Nishida A, Nishihara A, Iemura S, Natsume T, Akiyama T. The transmembrane nucleoporin NDC1 is required for targeting of ALADIN to nuclear pore complexes. Biochem Biophys Res Commun. 2009;389:100&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">19703420</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogliaghi G, Cangiano B, Duminuco P, Vezzoli V, Bonomi M. Triple-A syndrome (TAS): an in-depth overview on genetic and phenotype heterogeneity. Protein Pept Lett. 2020;27:1192&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">32533814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronshaw JM, Matunis MJ. The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome. Proc Natl Acad Sci USA. 2003;100:5823&#x2013;5827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156285</ArticleId><ArticleId IdType="pubmed">12730363</ArticleId></ArticleIdList></Reference><Reference><Citation>Huebner A, Kaindl AM, Knobeloch KP, Petzold H, Mann P, Koehler K. The triple A syndrome is due to mutations in ALADIN, a novel member of the nuclear pore complex. Endocr Res. 2004;30:891&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">15666842</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbholz M, Koehler K, Huebner A. Cellular localization of 17 natural mutant variants of ALADIN protein in triple A syndrome - shedding light on an unexpected splice mutation. Biochem Cell Biol. 2006;84:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">16609705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kind B, Koehler K, Krumbholz M, Landgraf D, Huebner A. Intracellular ROS level is increased in fibroblasts of triple A syndrome patients. J Mol Med (Berl) 2010;88:1233&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">20706703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano M, Furiya Y, Asai H, Yasui A, Ueno S. ALADINI482S causes selective failure of nuclear protein import and hypersensitivity to oxidative stress in triple A syndrome. Proc Natl Acad Sci USA. 2006;103:2298&#x2013;2303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413683</ArticleId><ArticleId IdType="pubmed">16467144</ArticleId></ArticleIdList></Reference><Reference><Citation>Storr HL, Kind B, Parfitt DA, Chapple JP, Lorenz M, Koehler K, Huebner A, Clark AJ. Deficiency of ferritin heavy-chain nuclear import in triple a syndrome implies nuclear oxidative damage as the primary disease mechanism. Mol Endocrinol. 2009;23:2086&#x2013;2094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419132</ArticleId><ArticleId IdType="pubmed">19855093</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai CX, Birk DE, Linsenmayer TF. Nuclear ferritin protects DNA from UV damage in corneal epithelial cells. Mol Biol Cell. 1998;9:1037&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25328</ArticleId><ArticleId IdType="pubmed">9571238</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KJ, Fried MG, Ye Z, Boyer P, Connor JR. Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei. J Cell Sci. 2002;115:2165&#x2013;2177.</Citation><ArticleIdList><ArticleId IdType="pubmed">11973357</ArticleId></ArticleIdList></Reference><Reference><Citation>Surguladze N, Patton S, Cozzi A, Fried MG, Connor JR. Characterization of nuclear ferritin and mechanism of translocation. Biochem J. 2005;388:731&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183451</ArticleId><ArticleId IdType="pubmed">15675895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sell K, Storch K, Hahn G, Lee-Kirsch MA, Ramantani G, Jackson S, Neilson D, von der Hagen M, Hehr U, Smitka M. Variable clinical course in acute necrotizing encephalopathy and identification of a novel RANBP2 mutation. Brain Dev. 2016;38:777&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">26923722</ArticleId></ArticleIdList></Reference><Reference><Citation>Fichtman B, Harel T, Biran N, Zagairy F, Applegate CD, Salzberg Y, Gilboa T, Salah S, Shaag A, Simanovsky N, Ayoubieh H, Sobreira N, Punzi G, Pierri CL, Hamosh A, Elpeleg O, Harel A, Edvardson S. Pathogenic variants in NUP214 cause "plugged" nuclear pore channels and acute febrile encephalopathy. Am J Hum Genet. 2019;105:48&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6612515</ArticleId><ArticleId IdType="pubmed">31178128</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseldin HE, Makhseed N, Ibrahim N, Al-Sheddi T, Alobeid E, Abdulwahab F, Alkuraya FS. NUP214 deficiency causes severe encephalopathy and microcephaly in humans. Hum Genet. 2019;138:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">30758658</ArticleId></ArticleIdList></Reference><Reference><Citation>Basel-Vanagaite L, Muncher L, Straussberg R, Pasmanik-Chor M, Yahav M, Rainshtein L, Walsh CA, Magal N, Taub E, Drasinover V, Shalev H, Attia R, Rechavi G, Simon AJ, Shohat M. Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis. Ann Neurol. 2006;60:214&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">16786527</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien ML, Lai JH, Lin TF, Yang WS, Juang YL. NUP62 is required for the maintenance of the spindle assembly checkpoint and chromosomal stability. Int J Biochem Cell Biol. 2020;128:105843.</Citation><ArticleIdList><ArticleId IdType="pubmed">32905854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnin E, Cabochette P, Filosa A, J&#xfc;hlen R, Komatsuzaki S, Hezwani M, Dickmanns A, Martinelli V, Vermeersch M, Supply L, Martins N, Pirenne L, Ravenscroft G, Lombard M, Port S, Spillner C, Janssens S, Roets E, Van Dorpe J, Lammens M, Kehlenbach RH, Ficner R, Laing NG, Hoffmann K, Vanhollebeke B, Fahrenkrog B. Biallelic mutations in nucleoporin NUP88 cause lethal fetal akinesia deformation sequence. PLoS Genet. 2018;14:e1007845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6307818</ArticleId><ArticleId IdType="pubmed">30543681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">21163446</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan S, Gao R, Bush K, Zhang N, Wairkar YP, Sarkar PS. Polyglutamine expansion in huntingtin and mechanism of DNA damage repair defects in Huntington's Disease. Front Cell Neurosci. 2022;16:837576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013776</ArticleId><ArticleId IdType="pubmed">35444517</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhr ST, Senut MC, Whitelegge JP, Faull KF, Cuizon DB, Gage FH. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol. 2001;153:283&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169460</ArticleId><ArticleId IdType="pubmed">11309410</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima JC, Daigle JG, Arbez N, Cunningham KC, Zhang K, Ochaba J, Geater C, Morozko E, Stocksdale J, Glatzer JC, Pham JT, Ahmed I, Peng Q, Wadhwa H, Pletnikova O, Troncoso JC, Duan W, Snyder SH, Ranum LPW, Thompson LM, Lloyd TE, Ross CA, Rothstein JD. Mutant huntingtin disrupts the nuclear pore complex. Neuron. 2017;94:93&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595097</ArticleId><ArticleId IdType="pubmed">28384479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Chillon-Marinas C, Goginashvili A, Atwal RS, Artates JW, Tabet R, Wheeler VC, Bang AG, Cleveland DW, Lagier-Tourenne C. Polyglutamine-expanded huntingtin exacerbates age-related disruption of nuclear integrity and nucleocytoplasmic transport. Neuron. 2017;94:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479704</ArticleId><ArticleId IdType="pubmed">28384474</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerner AC, Frottin F, Hornburg D, Feng LR, Meissner F, Patra M, Tatzelt J, Mann M, Winklhofer KF, Hartl FU, Hipp MS. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science. 2016;351:173&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26634439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp F, Vossfeldt H, Heinig M, Vasiljevic D, Arumughan A, Wyler E, Landthaler M, Hubner N, Wanker EE, Lannfelt L, Ingelsson M, Lalowski M, Voigt A, Selbach M. Quantitative interaction proteomics of neurodegenerative disease proteins. Cell Rep. 2015;11:1134&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014711</ArticleId><ArticleId IdType="pubmed">25959826</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH, Li XJ. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet. 2005;37:198&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654337</ArticleId></ArticleIdList></Reference><Reference><Citation>Havel LS, Wang CE, Wade B, Huang B, Li S, Li XJ. Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet. 2011;20:1424&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049362</ArticleId><ArticleId IdType="pubmed">21245084</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Li A, Holmes BB, Marasa JC, Diamond MI. An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1. J Biol Chem. 2013;288:6063&#x2013;6071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585045</ArticleId><ArticleId IdType="pubmed">23319588</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li SH, Johnston H, Shelbourne PF, Li XJ. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet. 2000;25:385&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932179</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Amieva H, Petersen RC, Ch&#xe9;telat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT. Alzheimer disease. Nat Rev Dis Primers. 2021;7:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Metuzals J, Robitaille Y, Houghton S, Gauthier S, Leblanc R. Paired helical filaments and the cytoplasmic-nuclear interface in Alzheimer's disease. J Neurocytol. 1988;17:827&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">3230400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield LG, Miskiewicz HB, Tannenbaum LB, Mirra SS. Nuclear pore complex proteins in Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410748</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HG, Ueda M, Miyamoto Y, Yoneda Y, Perry G, Smith MA, Zhu X. Aberrant localization of importin alpha1 in hippocampal neurons in Alzheimer disease. Brain Res. 2006;1124:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17070506</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto Y, Saiwaki T, Yamashita J, Yasuda Y, Kotera I, Shibata S, Shigeta M, Hiraoka Y, Haraguchi T, Yoneda Y. Cellular stresses induce the nuclear accumulation of importin alpha and cause a conventional nuclear import block. J Cell Biol. 2004;165:617&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172376</ArticleId><ArticleId IdType="pubmed">15184398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodiha M, Chu A, Matusiewicz N, Stochaj U. Multiple mechanisms promote the inhibition of classical nuclear import upon exposure to severe oxidative stress. Cell Death Differ. 2004;11:862&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">15088071</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Bardai FH, Feany MB. Lamin dysfunction mediates neurodegeneration in tauopathies. Curr Biol. 2016;26:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713335</ArticleId><ArticleId IdType="pubmed">26725200</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Bardai FH, Feany MB. Lamin dysfunction mediates neurodegeneration in tauopathies. Curr Biol. 2016;26:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713335</ArticleId><ArticleId IdType="pubmed">26725200</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelison GL, Levy SA, Jenson T, Frost B. Tau-induced nuclear envelope invagination causes a toxic accumulation of mRNA in Drosophila. Aging Cell. 2019;18:e12847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351838</ArticleId><ArticleId IdType="pubmed">30411463</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, Cook C, Miller SJ, Dujardin S, Amaral AS, Grima JC, Bennett RE, Tepper K, DeTure M, Vanderburg CR, Corjuc BT, DeVos SL, Gonzalez JA, Chew J, Vidensky S, Gage FH, Mertens J, Troncoso J, Mandelkow E, Salvatella X, Lim RYH, Petrucelli L, Wegmann S, Rothstein JD, Hyman BT. Tau protein disrupts nucleocytoplasmic transport in Alzheimer's disease. Neuron. 2018;99:925&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240334</ArticleId><ArticleId IdType="pubmed">30189209</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez L, Kapinos LE, Hochmair J, Huebschmann S, Dominguez-Baquero A, Vogt A, Rankovic M, Zweckstetter M, Lim RYH, Wegmann S. Phosphorylation but not oligomerization drives the accumulation of tau with nucleoporin Nup98. Int J Mol Sci. 2022;23:3495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8998617</ArticleId><ArticleId IdType="pubmed">35408855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34:404&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, Gupta S, Thomas MA, Hong I, Chiu SL, Huganir RL, Ostrow LW, Matunis MJ, Wang J, Sattler R, Lloyd TE, Rothstein JD. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW, 3rd, Sun S, Herdy JR, Bieri G, Kramer NJ, Gage FH, Van Den Bosch L, Robberecht W, Gitler AD. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, Petrucelli L, Kim HJ, Gao FB, Taylor JP. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutten S, Usluer S, Bourgeois B, Simonetti F, Odeh HM, Fare CM, Czuppa M, Hruska-Plochan M, Hofweber M, Polymenidou M, Shorter J, Edbauer D, Madl T, Dormann D. Nuclear import receptors directly bind to arginine-rich dipeptide repeat proteins and suppress their pathological interactions. Cell Rep. 2020;33:108538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814465</ArticleId><ArticleId IdType="pubmed">33357437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Duan L, Bowen K, Kalab P, Rothstein JD. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. Elife. 2020;9:e51685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanneste J, Vercruysse T, Boeynaems S, Sicart A, Van Damme P, Daelemans D, Van Den Bosch L. C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transport. Sci Rep. 2019;9:15728&#x2013;15728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6823349</ArticleId><ArticleId IdType="pubmed">31673013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, Sayegh M, Donlin-Asp PG, Chen YH, Duong DM, Seyfried NT, Powers MA, Kukar T, Hales CM, Gearing M, Cairns NJ, Boylan KB, Dickson DW, Rademakers R, Zhang YJ, Petrucelli L, Sattler R, Zarnescu DC, Glass JD, Rossoll W. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21:228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Yamashita T, Nakano Y, Morihara R, Li X, Feng T, Liu X, Huang Y, Fukui Y, Hishikawa N, Ohta Y, Abe K. Aberrant distributions of nuclear pore complex proteins in ALS mice and ALS patients. Neuroscience. 2017;350:158&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">28344074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC, Kumar MS, Ramesh N, Anderson EN, Nguyen AT, Kim B, Cheung S, McDonough JA, Skarnes WC, Lopez-Gonzalez R, Landers JE, Fawzi NL, Mackenzie IRA, Lee EB, Nickerson JA, Grunwald D, Pandey UB, Bosco DA. Interactions between ALS-linked FUS and nucleoporins are associated with defects in the nucleocytoplasmic transport pathway. Nat Neurosci. 2021;24:1077&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8832378</ArticleId><ArticleId IdType="pubmed">34059832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, Taylor JP, Gitler AD, Rothstein JD, Lloyd TE. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173:958&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Zaepfel BL, Hayes L, Fitchman B, Salzberg Y, Luo EC, Bowen K, Trost H, Aigner S, Rigo F, Yeo GW, Harel A, Svendsen CN, Sareen D, Rothstein JD. G4C2 repeat RNA initiates a POM121-mediated reduction in specific nucleoporins in C9orf72 ALS/FTD. Neuron. 2020;107:1124&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8077944</ArticleId><ArticleId IdType="pubmed">32673563</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Baskerville V, Zaepfel BL, Dickson DW, Rigo F, Bennett F, Lusk CP, Rothstein JD. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci Transl Med. 2021;13:eabe1923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022198</ArticleId><ArticleId IdType="pubmed">34321318</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Rothstein JD. The ESCRT-III protein VPS4, but not CHMP4B or CHMP2B, is pathologically increased in familial and sporadic ALS neuronal nuclei. Acta Neuropathol Commun. 2021;9:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287756</ArticleId><ArticleId IdType="pubmed">34281622</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, Moccia R, Cassel SH, Chen K, Wainger BJ, Woolf CJ, Eggan K. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, Ohkubo T, Rodriguez M, Lin N, Wu D, Bennett CF, Rigo F, Da Cruz S, Ravits J, Lagier-Tourenne C, Cleveland DW. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H, Teramoto S, Hideyama T, Kato H, Terashi H, Suzuki Y, Kimura T, Kwak S. Nuclear pore destruction and loss of nuclear TDP-43 in FUS mutation-related amyotrophic lateral sclerosis motor neurons. J Neurol Sci. 2022;436:120187.</Citation><ArticleIdList><ArticleId IdType="pubmed">35232585</ArticleId></ArticleIdList></Reference><Reference><Citation>Semmelink MFW, Steen A, Veenhoff LM. Measuring and interpreting nuclear transport in neurodegenerative disease-the example of C9orf72 ALS. Int J Mol Sci. 2021;22:9217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8431710</ArticleId><ArticleId IdType="pubmed">34502125</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>